Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Payables (2016 - 2026)

Mimedx's Payables history spans 17 years, with the latest figure at $11.5 million for Q1 2026.

  • On a quarterly basis, Payables rose 29.27% to $11.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $11.5 million, a 29.27% increase, with the full-year FY2025 number at $14.5 million, up 96.09% from a year prior.
  • Payables hit $11.5 million in Q1 2026 for Mimedx, down from $14.5 million in the prior quarter.
  • Over the last five years, Payables for MDXG hit a ceiling of $14.5 million in Q4 2025 and a floor of $6.9 million in Q3 2024.
  • Historically, Payables has averaged $9.1 million across 5 years, with a median of $8.5 million in 2025.
  • Biggest five-year swings in Payables: decreased 24.49% in 2024 and later skyrocketed 96.09% in 2025.
  • Tracing MDXG's Payables over 5 years: stood at $8.5 million in 2022, then grew by 7.03% to $9.0 million in 2023, then dropped by 18.11% to $7.4 million in 2024, then skyrocketed by 96.09% to $14.5 million in 2025, then fell by 21.09% to $11.5 million in 2026.
  • Business Quant data shows Payables for MDXG at $11.5 million in Q1 2026, $14.5 million in Q4 2025, and $11.4 million in Q3 2025.